Charles River Laboratories International, Inc. CRL
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Charles River Laboratories International, Inc. gets an algorithmic score of 44/100. It trades at 295.96 $, with a bullish technical trend (RSI 61.7) and 45.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- —
Weaknesses
- Low ROE (-7.5%).
- Thin net margin (-6.0%): vulnerable to costs.
Fundamentals
| Forward P/E | 23.24 |
| PEG | 0.12 |
| P/B | 4.97 |
| EV/EBITDA | 20.04 |
| P/S | 3.53 |
| ROE % | -7.52 |
| ROA % | 4.11 |
| Gross margin % | 34.59 |
| Operating margin % | 15.11 |
| Net margin % | -5.96 |
| Revenue growth % (y/y) | -2.70 |
| Revenue CAGR % | 0.33 |
| Debt/Equity % | 105.05 |
| Current ratio | 1.35 |
| FCF yield % | 3.67 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +1.5 % |
| 3 months | +30.5 % |
| 6 months | +85.3 % |
| YTD | +46.2 % |
| 1 year | +99.2 % |
| 3 years | +48.3 % |
| 5 years | -32.7 % |
Risk
| 1-year volatility | 45.8 % |
| Beta | 1.37 |
| 5-year max drawdown | -78.2 % |
| Sharpe 1A | 1.65 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.